Social Media

@vsanchorawala

Hematologist and Oncologist, Director, Amyloidosis Center @amyloidosis_bu. Hematologist and Oncologist @The_BMC

@MarthaGrogan1

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company's singular mission is…

@SLentzsch

Nephros, Inc. - Linkedin

Nephros is a commercial stage medical device company that develops and sells high-performance liquid purification filters. Nephros filters capture contaminants as…

@Ron_Witteles

BSIM Therapeutics - Linkedin

BSIM's mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and…

@rodney_falk

SOM Biotech - Linkedin

SOM Biotech is a clinical-stage drug discovery and development company based in Barcelona, Spain, with an office in the US, focused on repurposing drugs for CNS…

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.